KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775.

Vicky Makker, Nicoletta Colombo, Antonio Casado, Alessandro D Santin, Emeline Colomba, David S Miller, Keiichi Fujiwara, Sandro Pignata, Kan Yonemori, Yong Man Kim, Sally Baron-Hay, Isabelle Ray-Coquard, Ronnie Shapira-Frommer, Rebecca Kristeleit, Shin Nishio, Shiro Suzuki, Eva M Guerra Alía, Ulus A Sanli, Frederic Selle, Ayumi Shikama, Jorge L Martínez Rodríguez, Zafer Arik, Ali Arican, Alexandra Sebastianelli, Zhou Yu, Jodi McKenzie, Stephan Kruger, Robin Meng, Chinyere E Okpara, Domenica Lorusso

J Immunother Cancer 14(2) e013713

PMID41714113
PMCIDPMC12927346
DOI10.1136/jitc-2025-013713
发表日期2026-02-19
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BACKGROUND: In Study 309/KEYNOTE-775 (NCT03517449), lenvatinib+pembrolizumab versus chemotherapy significantly improved progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) in advanced endometrial cancer (EC). We report 5-year follow-up results. METHODS: Participants had advanced/recurrent/metastatic EC with progressive disease after one prior platinum-based chemotherapy regimen, measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1), and no prior receipt of anti-programmed cell death protein 1 or anti-programmed cell death ligand 1 agents. Participants were randomized 1:1 to lenvatinib 20 mg orally once daily plus pembrolizumab 200 mg intravenously every 3 weeks or chemotherapy (doxorubicin or paclitaxel). Pembrolizumab was given for ≤35 cycles. Primary endpoints were OS and PFS per RECIST v1.1 by blinded independent central review (BICR). Secondary endpoints included ORR per RECIST v1.1 by BICR and safety. Efficacy endpoints were analyzed using Cox regression, Kaplan-Meier, and Miettinen and Nurminen methodology. RESULTS: 827 participants were randomized. At data cut-off (February 26, 2025), overall median follow-up was 68.8 months; 139 participants were alive (lenvatinib+pembrolizumab, n=86; chemotherapy, n=53), and all had ended their treatment in this study. Five-year OS rate was 16.7% with lenvatinib+pembrolizumab versus 7.3% with chemotherapy in mismatch repair-proficient EC, 36.5% versus 9.8% in mismatch repair-deficient EC, and 19.9% versus 7.7% in all-comers. Five-year PFS rates were 6.3% versus 2.1%, 26.4% versus 10.8%, and 9.8% versus 3.2%, respectively. In all-comers, treatment-related adverse events led to any treatment discontinuation in 32.3% versus 5.9%. Subsequent systemic anticancer therapy was used by 44.8% versus 51.2% (lenvatinib+pembrolizumab by 2.4% vs 10.1%). CONCLUSIONS: Results were consistent with the primary analysis despite increased use of subsequent systemic anticancer therapy and crossover to lenvatinib+pembrolizumab in the chemotherapy group. The continued durable benefit, including OS, with lenvatinib+pembrolizumab and no new safety signals lend further support for this regimen as a standard of care therapy for EC.

KM 提取结果

2 个 Figure · 6 个 KM 面板

进入结果中心
KM Figure3 个面板

Figure 1

Figure 1. Overall survival in the ( A ) pMMR, ( B ) dMMR, and ( C ) all-comer populations. dMMR, mismatch repair-deficient; HR, hazard ratio; pMMR, mismatch repair-proficient.

A

Overall Survival

Figure 1 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

Overall Survival

Figure 1 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

Overall Survival

Figure 1 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure3 个面板

Figure 2

Figure 2. Progression-free survival per RECIST v1.1 by BICR in the ( A ) pMMR, ( B ) dMMR, and ( C ) all-comer populations. BICR, blinded independent central review; dMMR, mismatch repair-deficient; HR, hazard ratio; pMMR, mismatch repair-proficient; RECIST, Response Evaluation Criteria in Solid Tumors.

A

Progression-Free Survival

Figure 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:off origin start曲线 2:off origin start
查看结果
B

Progression-Free Survival

Figure 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme upward reversal
查看结果
C

Progression-Free Survival

Figure 2 · Panel C

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel C 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 3Figure 3. Duration of response per RECIST v1.1 by BICR in the ( A ) pMMR, ( B ) dMMR, and ( C ) all-comer populations. BICR, blinded independent central review; dMMR, mismatch repair-deficient; pMMR, mismatch repair-proficient; RECIST, Response Evaluation Criteria in Solid Tumors.
非 KM Figure
Figure 4Figure 4. Tornado plot of most frequent treatment-related adverse events (≥20% in either treatment group) in all participants in the safety analysis population.
非 KM Figure